Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) Bundle
Nanjing King‑Friend Biochemical Pharmaceutical Co., Ltd. has transformed from a domestic API maker into a global life‑science contender, publicly listed with a market capitalization exceeding $3 billion USD and a diversified portfolio that generated over $200 million in API sales and more than $300 million in FDF sales, backed by three FDA‑approved facilities capable of producing over 200 million syringes and 200 million vials annually; its strategic pivot toward high‑end formulations and sterile injectables helped international markets account for 76.75% of 2024 revenue while the company delivered a striking financial turnaround with a 2024 net profit of 0.826 billion yuan - up 536.09% year‑on‑year - supported by sustained investment in innovation (allocating approximately 8% of annual revenue to R&D and reporting $15 million in R&D spend in 2023, about 10% of revenue), a vision for global leadership and carbon neutrality by 2030, and core values centered on quality, ethics, sustainability and collaborative advancement of anticoagulants and advanced injectables.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Intro
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) is a publicly listed Chinese pharmaceutical manufacturer established in 1986, with a market capitalization exceeding $3 billion USD. The company concentrates on Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), and has strategically shifted toward high-end formulations and international sterile injectables.- Founded: 1986
- Listing: Shanghai Stock Exchange (603707.SS)
- Market capitalization: > $3 billion USD
- International revenue (2024): 76.75% of total
| Metric | 2024 Figure / Status |
|---|---|
| Net profit | 0.826 billion CNY (YoY +536.09%) |
| API sales | > $200 million USD |
| FDF sales | > $300 million USD |
| FDA‑approved facilities | 3 facilities |
| Annual sterile capacity | > 200 million syringes; > 200 million vials |
| CDE‑approved drugs | Developed > 10 drugs |
| U.S. ANDAs | > 60 ANDAs |
- Deliver high-quality, safe pharmaceutical products globally, prioritizing sterile injectable innovation and reliable API supply chains.
- Drive patient access through scalable manufacturing and regulatory excellence.
- Be a leading global supplier of advanced sterile injectables and finished dosage forms, expanding market presence across developed markets.
- Transform into a top-tier, innovation-driven pharma enterprise with sustainable international growth.
- Quality & Compliance - maintain FDA approvals and robust regulatory track record.
- Patient‑centricity - ensure product safety and availability for clinicians and patients worldwide.
- Innovation - invest in high-end formulations and sterile technologies.
- Global Orientation - prioritize export markets (76.75% revenue from international sales in 2024).
- Operational Excellence - scale manufacturing (200M+ syringes/vials annually) while optimizing cost and quality.
- Portfolio balance: API (> $200M) and FDF (> $300M) revenue streams support margin diversification.
- Sterile injectable focus: three FDA‑approved facilities enable large-scale supply to regulated markets.
- Regulatory footprint: >10 CDE approvals and 60+ U.S. ANDAs support market access and growth in developed markets.
- Financial turnaround: 2024 net profit of 0.826 billion CNY, a 536.09% YoY increase, reflecting margin recovery and higher-value product mix.
| Area | Implication |
|---|---|
| High international revenue share (76.75%) | Exposure to foreign markets and stronger USD/CNY dynamics; scalability and pricing power in developed markets. |
| Large sterile capacity | Ability to capture tender and commercial injectable contracts; supports rapid volume expansion. |
| ANDAs portfolio | Pipeline for U.S. generics entry and recurring revenue streams upon approvals. |
| Revenue mix (API vs FDF) | Balanced income sources: APIs > $200M and FDFs > $300M enable vertical integration advantages. |
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Overview
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) positions its corporate purpose around improving quality of life by delivering high-quality pharmaceutical products, pursuing continuous innovation, and maintaining strong customer and patient focus. The company emphasizes therapeutic leadership in anticoagulants and advanced injectable formulations while embedding sustainability and responsible sourcing into its operating model.- Mission: Enhance people's quality of life through perseverance and dedication to health, driven by product quality, innovation, and patient-centric service.
- R&D commitment: Allocates approximately 8% of annual revenue to research and development to accelerate pipeline growth and formulation improvements.
- Sustainability: Integrates environmentally friendly production practices and sustainable sourcing across its supply chain.
- Strategic aim: Become a first-class enterprise in global pharmaceutical and healthcare markets, expanding both product breadth and international reach.
- Clinical focus: Improve patient outcomes through innovative treatments, with particular emphasis on anticoagulants and advanced injectable therapies.
| Metric | Approximate Value / Note |
|---|---|
| Annual revenue (most recent reporting period) | ≈ CNY 2.2-2.8 billion (company-scale range; subject to annual reporting) |
| R&D investment (% of revenue) | ≈ 8% of annual revenue (company-stated commitment) |
| Estimated R&D spend (monetary) | ≈ CNY 176-224 million (derived from revenue range × 8%) |
| Employees | ≈ 1,200-1,800 (manufacturing, R&D, commercial teams) |
| Export / international sales share | ≈ 20-35% (growing focus on overseas markets) |
| Therapeutic revenue concentration | Anticoagulants and injectables represent a leading share-estimated ≈ 30-45% of product sales |
| Environmental & sustainability targets | Progressive reduction of emission and waste intensity; increased use of sustainable raw material sourcing |
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Mission Statement
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) positions its mission around delivering high-quality, reliable pharmaceutical products while expanding global reach in high-end injectable medicines and advancing sustainable, ethical operations.- Deliver safe, quality-assured essential medicines and high-end injectables to healthcare systems worldwide.
- Advance life-science innovation through targeted R&D, strategic partnerships, and technology-driven manufacturing.
- Operate with integrity, regulatory compliance, and transparent governance as a listed company on the Shanghai Stock Exchange (603707.SS).
- Pursue measurable environmental responsibility, aiming for carbon neutrality by 2030.
- Build long-term trust with customers, partners, and communities through consistent supply and service excellence.
- Aim: Become a first-class enterprise in the global pharmaceutical and healthcare markets.
- Leadership: Be recognized for innovative therapeutic solutions and exceptional manufacturing quality.
- Global footprint: Expand exports and regulatory filings in key markets for high-end injectable therapeutics.
- Trust & reliability: Ensure stable supply chains for essential medicines to hospitals and distributors.
- Sustainability: Attain carbon neutrality by 2030 across operations and production facilities.
- Reputation: Establish leading brand medicines and be a respected service provider in healthcare.
| Priority | Target / Indicator | Timeframe |
|---|---|---|
| High-end injectables expansion | Increase authorized injectable SKUs and regulated-market registrations | Ongoing; accelerated 3-5 year plan |
| Quality & compliance | Maintain GMP certifications; zero major regulatory sanctions | Continuous |
| Supply reliability | Stable fill rates to major hospital clients; reduce stockouts | Annual KPIs |
| Carbon neutrality | Net-zero scope 1-2 emissions target | 2030 |
| R&D & innovation | Invest in formulation and process development; expand technical partnerships | Ongoing |
| Corporate governance | Transparent reporting as 603707.SS listed entity | Quarterly/annual disclosures |
- Listed ticker: 603707.SS on the Shanghai Stock Exchange.
- Product focus: generic and branded sterile injectables, essential medicines for hospital use.
- Environmental commitment: public pledge to achieve carbon neutrality by 2030.
- Stakeholder trust: emphasis on consistent supply to institutional buyers and distributors.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Vision Statement
Nanjing King-Friend envisions becoming a global leader in biochemical and pharmaceutical innovation, delivering safer, more effective therapies while driving sustainable growth for stakeholders and uplifting the communities it serves. The company's vision is grounded in measurable investments and a clear commitment to ethics, people, and technological advancement.- Innovation: R&D expenditure of $15 million in 2023, representing 10% of total revenue (implying 2023 revenue of approximately $150 million).
- Ethical conduct: Upholding the highest standards in governance, compliance, and responsible business practices across operations and supply chains.
- People-first commitment: Prioritizing the health, safety, development, and well-being of employees, customers, and communities.
- Excellence & continuous improvement: Systematic quality enhancement across R&D, manufacturing, and commercialization to elevate product safety and efficacy.
- Collaborative culture: Fostering teamwork, mutual respect, and cross-disciplinary collaboration to accelerate scientific breakthroughs.
- Technology adoption: Embracing new ideas and emerging technologies to drive both scientific advancement and business growth.
| Metric | 2023 Value |
|---|---|
| R&D Expenditure | $15,000,000 |
| R&D as % of Revenue | 10% |
| Estimated Total Revenue | $150,000,000 |
- Strategic focus areas: translational research, biologics development, process optimization, and digital-enabled drug discovery.
- Governance & ethics pillars: transparency, regulatory compliance, patient safety, and anti-corruption measures embedded in corporate policy.
- Community impact: targeted health initiatives and local partnerships to support access to medicines and workforce development.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.